-+ 0.00%
-+ 0.00%
-+ 0.00%

ALTIMMUNE ANNOUNCES THAT PEMVIDUTIDE ACHIEVED KEY MEASURES OF SUCCESS AT 48 WEEKS IN IMPACT PHASE 2B MASH TRIAL

Reuters·12/19/2025 11:30:00

Please log in to view news